FDA Sends Warning Letter After Chinese Supplier Breaks GLP-1 Import Restrictions

Why It Matters

The enforcement action signals that the FDA will rigorously police the new GLP‑1 import restrictions, protecting patients from substandard APIs and forcing overseas manufacturers to tighten supply‑chain transparency.

Key Takeaways

• FDA added Jixianglong to green list, then found compliance breach.
• Company sourced semaglutide from unapproved supplier and mislabelled origin.
• Improper repackaging, missing batch records violated FDA import alert.
• FDA urged recall; batches withdrawn from US market in February.

Pulse Analysis

The FDA’s March 2025 import alert created a "green list" to vet foreign facilities supplying GLP‑1 receptor agonist APIs, a response to explosive demand for obesity and diabetes treatments. By limiting entry to verified sources, regulators aim to curb counterfeit or substandard ingredients that could jeopardize patient safety. The policy forces overseas manufacturers to secure formal approvals and maintain rigorous documentation, reshaping the global supply chain for high‑margin drugs such as semaglutide and tirzepatide.

Harbin Jixianglong Biotech’s breach illustrates the practical challenges of compliance. Although the firm earned green‑list status, it later sourced semaglutide from an unapproved Chinese plant, repackaged the product, and altered manufacturing dates to appear compliant. The FDA’s inspection uncovered missing batch records and inadequate validation procedures, prompting a Form 483 and a warning letter. The company’s admission that it occasionally purchases APIs externally highlights a tension between meeting U.S. demand and adhering to strict import safeguards, forcing compounding pharmacies to scrutinize their ingredient provenance more closely.

Going forward, the episode is a cautionary tale for all API exporters targeting the U.S. market. Regulators are likely to increase on‑site inspections, expand the green‑list criteria, and impose swift recalls for non‑conforming shipments. Companies must invest in robust traceability systems, third‑party verification, and transparent labeling to avoid costly penalties and supply disruptions. For U.S. drug manufacturers, the heightened oversight may encourage sourcing from established, vetted partners, ultimately stabilizing the GLP‑1 market while safeguarding patient health.